Prospective Study
Copyright ©The Author(s) 2015.
World J Clin Oncol. Oct 10, 2015; 6(5): 156-165
Published online Oct 10, 2015. doi: 10.5306/wjco.v6.i5.156
Table 3 Esophagitis and pneumonitis rates in prospective trials evaluating concurrent chemoradiation in inoperable stage III non-small cell lung cancer
Ref.YearDesignNo. of patientsNodesRT dose (Gy)ChemoGrade 3-4esophagitisGrade 3-4pneumonitis
Furuse et al[27]1999Ind → RT314ENI56Cis/Vnd/Mit3%-
CCRT5612%1%
Zatloukal et al[28]2004Ind → RT102ENI60Cis/Vno4%
CCRT18%4%
Fournel et al[26]2005Ind → RT205ENI66Cis/Vno2%
CCRT → ConsCis/Eto → Cis/Vno32%5%
Belani et al[4]2005Ind → RT257IFRT63Cbp/Pac--
Ind → CCRT19%4%
CCRT → Cons28%16%
Vokes et al[2]2007CCRT366ENI66Cbp/Pac28%4%
Ind → CCRT30%10%
Belderbos et al[25]2007Ind → RT158ENI662Cis/Gem5%
CRTCis14%18%
Socinski et al[41]2008Ind → CCRT69“ENI discouraged but allowed”74Cbp/Pac16%16%
Ind → CRTCbp/Gem39%37%
Blumenschein et al[23]2011CCRT87“Selective nodal irradiation”63Cbp/Pac/8%22%
Cet
Curran et al[42]2011Ind → RT407ENI63Cis/Vnb4%-
CCRT63Cis/Vnb22%13%
CCRT69.63Cis/Eto45%15%
Hoang et al[5]2012CCRT546IFRT60Cbp/Pac< 1%1%
CCRT + ThlCbp/Pac/Thl< 1%1%